Compare GSK plc (GSK) vs Vanguard Tax Managed Fund FTSE Developed Markets ETF (VEA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Vanguard Tax Managed Fund FTSE Developed Markets ETF — how do they compare? GSK plc trades at $46.62 (market cap $91.88B), while Vanguard Tax Managed Fund FTSE Developed Markets ETF trades at $70.27 (market cap $323.80B). The key difference: Vanguard Tax Managed Fund FTSE Developed Markets ETF is far larger — about 3.5× GSK plc's market cap, and GSK plc pays a 3.9% dividend while Vanguard Tax Managed Fund FTSE Developed Markets ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold GSK plc for 93 Days and Vanguard Tax Managed Fund FTSE Developed Markets ETF for 131 Days on average.
| GSK | VEA | |
|---|---|---|
Market Cap | $91.88B | $323.80B |
Volume | 7,730,529 | 17,001,112 |
Sector | Health | — |
52-Week High | $61.18 | $73.79 |
52-Week Low | $43.24 | $58.90 |
Typical Hold Time | 93 Days | 131 Days |
Enterprise Value | $111.88B | — |
Dividend Yield | 3.9% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $46.45, down 1.21% with bearish technical signals. The company shows strong fundamentals with revenue growth to $32.67B in 2025 and consistent earnings beats. Valuation metrics appear reasonable with P/E of 14.89 and EV/EBITDA of 8.75. Recent developments include strategic oncology partnerships and a $750M cancer therapy acquisition, positioning for long-term growth despite near-term technical weakness.
GSK presents a mixed outlook with strong profitability and pipeline expansion offset by technical bearishness and HIV patent concerns. The company's 29.73% ROE and recent earnings outperformance support investment appeal, while the bearish moving average signal and competitive pressures warrant caution. Analyst consensus leans hold with 55% neutral rating, suggesting balanced risk-reward for long-term investors.
VEA trades at $70.21, down 0.07% with bearish technical signals dominating. The ETF shows mixed institutional activity with several firms increasing positions while others reduced exposure. Recent news highlights VEA's competitive advantages including its 0.03% expense ratio and focus on developed markets excluding the U.S. The current technical setup shows oversold conditions with RSI at 28.40 suggesting potential near-term bounce opportunity.
VEA presents a cost-efficient developed markets exposure with strong dividend yield appeal, though technical indicators signal caution. Key risks include global market volatility and currency fluctuations. The ETF's institutional ownership trends and competitive expense ratio support its long-term positioning for investors seeking international diversification beyond U.S. markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Vanguard Tax Managed Fund FTSE Developed Markets ETF
The fund employs an indexing investment approach designed to track the performance of the FTSE Developed All Cap ex US Index, a market-capitalization-weighted index that is made up of approximately 4022 common stocks of large-, mid-, and small-cap companies located in Canada and the major markets of Europe and the Pacific region. The advisor attempts to replicate the target index by investing all, or substantially all, of its assets in the stocks that make up the index, holding each stock in approximately the same proportion as its weighting in the index.
Read more on VEA →
